Drug analysis

A
B-C
D-F
Drug Analysis
G-L
M-O
P-R
S-T
U-Z

Sort by Default

Display 15 Products per page

fostemsavir
Read More
Fostemsavir (GSK3684934) (ViiV Healthcare), previously known as BMS-663068, is an oral prodrug of GSK2616713 (formerly BMS-626529). It is an attachment inhibitor which binds to the gp120 protein of HIV to prevent viral attachment to the host CD4+ T cells, which is necessary for entry into host cells.
June 28, 2019
Find out more
leronlimab
Read More
Leronlimab (CytoDyn) is a humanized monoclonal antibody directed against C-C chemokine receptor 5 (CCR5), which is a co-receptor required for the attachment and entry of CCR5-tropic HIV-1 viruses into host cells.
June 28, 2019
Find out more
Complera
Read More
Complera (rilpivirine/emtricitabine/tenofovir disoproxil fumarate [TDF]; Gilead/Johnson & Johnson) is a single-tablet regimen for the treatment of HIV-1 infection.
June 28, 2019
Find out more
Atripla
Read More
Atripla (efavirenz/emtricitabine/tenofovir disoproxil fumarate [TDF]; Gilead/Bristol-Myers Squibb) is a single-tablet regimen approved for the treatment of HIV-1 infection.
June 28, 2019
Find out more
Reyataz
Read More
The Reyataz franchise comprises the standalone azapeptide protease inhibitor (PI) Reyataz (atazanavir; Bristol-Myers Squibb) and the fixed-dose combination of Reyataz and Tybost.
June 28, 2019
Find out more
Isentress
Read More
Isentress (raltegravir; Merck & Co) is a twice-daily, unboosted integrase inhibitor (INI) that is used in combination with other antiretroviral drugs for treatment of HIV-1 infection.
June 28, 2019
Find out more
Genvoya
Read More
Genvoya (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide fumarate [TAF]; Gilead) is a single-tablet regimen (STR) approved for the treatment of HIV-1 infection.
June 28, 2019
Find out more
Stribild
Read More
Stribild (elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate [TDF]; Gilead/Japan Tobacco) is a single-tablet regimen for the treatment of HIV-1 infection. It is a co-formulation of marketed fixed-dose combination (FDC) Truvada, Vitekta, and Tybost.
June 28, 2019
Find out more
Prezista franchise
Read More
The Prezista franchise comprises the standalone protease inhibitor (PI) Prezista (darunavir; Johnson & Johnson) and the fixed-dose combination of Prezista and Tybost (cobicistat; Gilead), which is branded as Prezcobix in the US and Rezolsta in the EU.
June 28, 2019
Find out more
Triumeq
Read More
Triumeq ([dolutegravir + abacavir + lamivudine]; ViiV Healthcare) is a single-tablet regimen (STR) for the treatment of HIV-1 infection. It is a co-formulation of the marketed HIV drugs Tivicay (dolutegravir; ViiV Healthcare) and Epzicom ([abacavir + lamivudine]; ViiV Healthcare), which is known as Kivexa outside the US. Tivicay is an integrase inhibitor that blocks the insertion of the viral genome into the host genome, and Epzicom is a fixed-dose combination nucleoside reverse transcriptase inhibitor that prevents viral RNA replication.
June 28, 2019
Find out more
Tivicay
Read More
Tivicay (dolutegravir; ViiV Healthcare) is a once-daily, unboosted integrase inhibitor (INI) for the treatment of HIV-1 infection.
June 28, 2019
Find out more
Fetzima
Read More
Fetzima (levomilnacipran; Allergan) is a serotonin-norepinephrine reuptake inhibitor indicated for the treatment of major depressive disorder (MDD) in the US.
March 29, 2019
Find out more
Travivo
Read More
Travivo (gepirone ER; GlaxoSmithKline/Mission Pharmacal) is a pyridinyl piperazine 5-HT1A receptor agonist, and is distinct from available therapies as it is not a reuptake inhibitor and has no material norepinephrine or dopamine activity. Unlike tricyclic antidepressants or selective serotonin reuptake inhibitors that act on most or all of the 5-HT subtypes in the brain and may have several adverse effects, trials for Travivo have shown benign adverse effects without significant dopaminergic effects.
March 29, 2019
Find out more
SAGE-217
Read More
SAGE-217 (oral brexanolone; SAGE Therapeutics/Shionogi) is a novel, next-generation positive allosteric modulator that selectively binds synaptic and extrasynaptic gamma-aminobutyric acid-A (GABA-A) receptors and shares similar pharmacology properties to brexanolone.
March 29, 2019
Find out more
Zulresso
Read More
Zulresso is SAGE Therapeutics’ proprietary intravenous formulation of brexanolone, which is an allosteric modulator of both synaptic and extra-synaptic GABA-A receptors.
March 29, 2019
Find out more

Sign up to the Pharma Intelligence Report Store Newsletter to get the latest blogs, news, reports and discounts!

Pharma Intelligence is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726

Call Back

Name

Email *

Company name *

Phone number *